• Explore /
  • Poster
  • / Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.

Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.

Abstract Poster

Authors

null

Shanu Modi

Memorial Sloan Kettering Cancer Center, New York, NY

Shanu Modi , Naoki Niikura , Toshinari Yamashita , William Jacot , Joohyuk Sohn , Eriko Tokunaga , Maria Jesus Vidal , Yeon Hee Park , Keun Seok Lee , Yeesoo Chae , Naoto T. Ueno , Aleix Prat , Fumitaka Suto , Yusuke Kuwahara , Robert McEwen , Wenqin Feng , Hiroki Goto , Cecilia Orbegoso , David A. Cameron , Junji Tsurutani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Clinical Trial Registration Number

NCT03734029

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1020)

DOI

10.1200/JCO.2023.41.16_suppl.1020

Abstract #

1020

Poster Bd #

241

Abstract Disclosures

Similar Posters

First Author: Malinda T West

First Author: Fabrice Andre

First Author: Seth Andrew Wander

First Author: Cristina I. Truica